General Information
Drug ID
DR00407
Drug Name
Nateglinide
Synonyms
(2R)-3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid; 3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid; A-4166; AY-4166; DJN 608; DJN-608; Fastic; IPCCPA; N-((4-isopropylcyclohexyl)carbonyl)phenylalanine; N-{[4-(propan-2-yl)cyclohexyl]carbonyl}phenylalanine; N-{[trans-4-(propan-2-yl)cyclohexyl]carbonyl}-D-phenylalanine; Nate-glinide; Nateglinide [INN]; Nateglinide, (D-Phe)-isomer; Nateglinide, (cis,D-Phe)-isomer; Novartis brand of nateglinide; SDZ-DJN-608; Senaglinide; Starlix; Starlix (TN); Starsis; Trazec; YM-026
Drug Type
Small molecular drug
Indication Diabetes [ICD11: 5A10-5A14] Approved [1]
Therapeutic Class
Hypoglycemic Agents
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=5311309"></iframe>
3D MOL 2D MOL
Formula
C19H27NO3
Canonical SMILES
CC(C)C1CCC(CC1)C(=O)NC(CC2=CC=CC=C2)C(=O)O
InChI
InChI=1S/C19H27NO3/c1-13(2)15-8-10-16(11-9-15)18(21)20-17(19(22)23)12-14-6-4-3-5-7-14/h3-7,13,15-17H,8-12H2,1-2H3,(H,20,21)(H,22,23)/t15-,16-,17-/m1/s1
InChIKey
OELFLUMRDSZNSF-BRWVUGGUSA-N
CAS Number
CAS 105816-04-4
Pharmaceutical Properties Molecular Weight 317.429 Topological Polar Surface Area 66.4
Heavy Atom Count 23 Rotatable Bond Count 6
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 3
XLogP
3.2
PubChem CID
5311309
PubChem SID
103206766 , 104253649 , 114155796 , 117890894 , 12013966 , 124658899 , 124757828 , 124801358 , 125164632 , 126630653 , 126657177 , 128797137 , 128797139 , 128797141 , 131293719 , 131347903 , 131860350 , 135692483 , 136949105 , 137129256 , 137175459 , 137231395 , 140330680 , 142491149 , 142619974 , 143248460 , 144204985 , 14752539 , 14874578 , 151981031 , 152100318 , 26719880 , 37101837 , 39341005 , 46386701 , 46504836 , 49681657 , 49830241 , 56313768 , 57359430 , 582898 , 75919327 , 7848174 , 7980094 , 81092826 , 91748929 , 92308370 , 92308686 , 92711649 , 93166415
ChEBI ID
ChEBI:31897
TTD Drug ID
D06PSS
DT(s) Transporting This Drug MCT6 Transporter Info Monocarboxylate transporter 6 Substrate [2]
OATP1B1 Transporter Info Organic anion transporting polypeptide 1B1 Substrate [3]
OATP1B3 Transporter Info Organic anion transporting polypeptide 1B3 Substrate [4]
References
1 Nateglinide was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Quercetin, Morin, Luteolin, and Phloretin Are Dietary Flavonoid Inhibitors of Monocarboxylate Transporter 6. Mol Pharm. 2017 Sep 5;14(9):2930-2936.
3 Organic Anion Transporter 2-Mediated Hepatic Uptake Contributes to the Clearance of High-Permeability-Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs. J Pharmacol Exp Ther. 2018 Nov;367(2):322-334.
4 FDA Drug Development and Drug Interactions

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.